Anne U. Goeppert
AstraZeneca (United States)(US)
Publications by Year
Research Areas
DNA and Nucleic Acid Chemistry, Estrogen and related hormone effects, Ubiquitin and proteasome pathways, Cancer therapeutics and mechanisms, Chemical Reaction Mechanisms
Most-Cited Works
- → Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists(2016)364 cited
- → Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily(2017)85 cited
- → Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease(2017)69 cited
- → Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations(2016)28 cited
- → A flexible high content imaging assay for profiling macrophage efferocytosis(2019)9 cited
- → BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5(2023)8 cited
- → Abstract P3-04-10: Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer(2017)
- → Data from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists(2023)
- → Supplementary Figures 1 - 8, Tables 1 - 3 from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists(2023)
- → Supplementary Methods from Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists(2023)